Compare Prudential Financial Inc (PRU) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prudential Financial Inc vs TransMedics Group Inc — how do they compare? Prudential Financial Inc trades at $117.62 (market cap $40.57B), while TransMedics Group Inc trades at $86.5 (market cap $3.00B). The key difference: Prudential Financial Inc is far larger — about 13.5× TransMedics Group Inc's market cap, and Prudential Financial Inc pays a 4.76% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| PRU | TMDX | |
|---|---|---|
Market Cap | $40.57B | $3.00B |
Sector | Financials | Technology |
52-Week High | $125.13 | $150.42 |
52-Week Low | $92.00 | $61.99 |
Enterprise Value | $69.35B | $3.39B |
Dividend Yield | 4.76% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Prudential Financial (PRU) trades at $119.38, down 2.16% today, with a neutral technical signal and bearish moving averages. The stock shows attractive valuation metrics with a P/E of 10.82 and P/S of 0.64, while recent earnings beat expectations in Q1 and Q2 2026. Revenue for 2025 was $60.97B with net income of $3.58B, and the company maintains a solid dividend of $1.40 per share. Recent news highlights participation in investor conferences and new product launches.
The outlook for PRU is mixed; fundamentals are strong with improving profitability and low valuation, but technical indicators and analyst consensus suggest caution. Risks include volatile cash flows and high debt levels. Wall Street sentiment is neutral with a consensus price target of $113.20, below the current price, indicating limited near-term upside potential.
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings performance. The company reported strong 2025 results with $605M revenue and 31.4% net margin, though 2026 projections show margin compression. Recent news highlights growth initiatives in kidney transplantation and European markets, alongside ongoing legal investigations into fiduciary duties.
The stock offers upside to the $99.57 consensus price target, supported by analyst bullishness (69% buy ratings), but faces risks from margin pressure, legal scrutiny, and earnings misses. Revenue growth remains a key catalyst, though execution risks and investor sentiment headwinds warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Prudential Financial Inc
Prudential Financial is a large, diversified insurance company offering annuities, life insurance, retirement plan services, and asset management products. While it operates in a number of countries, the vast majority of revenue is generated in the United States and Japan. The company's investment management business, PGIM, contributes approximately 15% of its earnings and has over $1.5 trillion in assets under management. The U.S. businesses are responsible for about 45% of earnings and can be classified into Institutional Retirement Strategies, Individual Retirement Strategies, Group Insurance, Individual Life Insurance, and Assurance IQ. Finally, the international business segment of the company contributes approximately 40% of earnings with a strong market position in Japan.
Read more on PRU →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
